Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
I-Mab Biopharma
Sort By
Newest First
Sign in
1 / 1
1 / 1
Announcement
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
I-Mab
PR-10-24-NI-80
Nov 07, 2024
Partnership
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie
PR-M09-20-NI-06
Sep 04, 2020
Strategic Partnership
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
WuXi Biologics
PR-M04-19-NI-065
Apr 19, 2019
FDA Approval
I-Mab Receives IND Approval from the US FDA to Initiate Clinical Trials for Its Proprietary TJC4, a Potential Global Best-in-Class Anti-CD47 Monoclonal Antibody
I-Mab
PR-M01-19-NI-082
Jan 29, 2019
Immunotherapy
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy
I-Mab
PR-M11-18-NI-014
Nov 05, 2018
Global Collaboration
ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies
ABL Bio
PR-M08-18-NI-005
Aug 01, 2018
Global Collaboration
I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies
I-Mab
PR-M07-18-NI-107
Jul 31, 2018
